Nuvilex Says Phase III Trials for Pancreatic Cancer Could Make “Cell-in-a Box” a Gold Standard

Nuvilex Inc. (OTCQB:NVLX) announced that its “Cell-in-a-Box” technology, a process that creates a “platform” upon which treatments for many serious diseases may be built, is off to a great start.

As quoted in the press release:

Nipping at Eli Lilly’s heels are both Celgene and Nuvilex, but of the three, the smallest of them all, has produced the best results in clinical trials using its living cell encapsulation.

Click here to read the full Nuvilex Inc. (OTCQB:NVLX) press release.